Pharmaceutical company Alvogen revealed on Wednesday the availability of its generic equivalent of Suboxone sublingual film (buprenorphine hydrochloride/naloxone hydrochloride) in the US in 2mg/0.5 mg, 4mg/1mg, 8 mg/2mg and 12mg/3mg strengths.
The company said the Suboxone sublingual film is indicated for treatment of opioid dependence.
Based on Indivior SEC Filings, the US sales for Suboxone were approximately USD1.1bn in 2018.
Suboxone, which is a registered trademark of Indivior UK LLC, follows the issuance of a mandate from the US Court of Appeals for the Federal Circuit vacating the preliminary injunction that had been granted enjoining Dr. Reddy's Laboratories from marketing its product.
EirGenix signs second global exclusive licensing deal with Sandoz
Padagis invests USD36m to expand manufacturing in Minneapolis
Newbury Pharmaceuticals gains Danish approval for generic ivermectin cream
Esperion settles with Dr. Reddy's Laboratories on NEXLETOL and NEXLIZET generics
Mint Pharmaceuticals forms distribution partnership with Bayer Canada
Padagis collaborates with The Naloxone Project to address opioid overdose crisis
Zentiva announces sale from Advent to GTCR
Biocon's first US manufacturing facility inaugurated in Cranbury, New Jersey
Amneal's risperidone extended-release injectable suspension approved by US FDA
First FDA acceptance to waive clinical efficacy studies for monoclonal antibody biosimilars
Coya Therapeutics wins FDA clearance to advance COYA 302 into Phase 2 ALS trial
Viatris' generic iron sucrose injection gains US FDA approval
Newbury Pharmaceuticals gains Finnish approval for generic melatonin
CivicaScript to distribute biosimilar for chronic inflammatory conditions